The Short Version: There are really only two choices here
At the European Association for the Study of Diabetes conference in September 2024, researchers reported that in early trials, amycretin led to a 10.4% loss of body weight in people who were overweight or obese when taken at its lowest dose for 12 weeks
Having said that, the research done thus far does suggest that females taking GLP-1s may be twice as likely to experience side effects in general
GHK-Cu is a small peptide bound to a copper ion (the Cu) that occurs naturally in the body
By activating the Nrf2 pathway, sulforaphane has been shown in clinical trials to help with neuroinflammation, mental health, prostate cancer prevention, asthma, and inflammation
Sermorelin has none of that visceral-fat-specific evidence base